IL6 and non-small cell lung carcinoma: In non-small-cell lung cancer (NSCLC), SNHG3 activation by E2F1 drives proliferation and migration via the TGF-β and IL-6/JAK2/STAT3 pathways, underscoring its therapeutic relevance [33].